BioSpace News Archive

CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors as Chairman, effective immediately. Dr. Pomerantz is currently the President, Chief Executive Officer and Chairman of the Board of Directors of ContraFect.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will feature 11 presentations, including 10 posters, and one oral presentation highlighting its ongoing studies and commitment to rare lysosomal storage disorders at the 16th annual WORLDSymposium™ 2020 in Orlando, Florida, February 10-13.

Allergan plc reported its full-year and fourth quarter 2019 financial results including full-year 2019 GAAP net revenues of $16.1 billion, a 1.9 percent increase from 2018.

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a public offering registered under the Securities Act of 1933, as amended.

SAN CARLOS, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first subject in AKST4290-205 (PHTHALO), which will assess the effects of AKST4290 on visual acuity with loading doses of anti-VEGF in treatm

Feb. 10, 2020 12:45 UTC “Take on Acne” ad campaign emphasizes the discomfort and disruption caused by acne, especially among teens and young adults PRINCETON, N.J.--( BUSINESS WIRE )-- Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc., USA, which is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (together “Sun Pharma”), today announced the launch of Take on Acne – a new advertising campaign designed to raise awareness of the profound imp

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that new clinical data on the Company’s first-in-class, late-stage asset, Plinabulin, shows its ability to potently stimulate the innate immune system.

NEWTOWN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference, February 17-18, 2020, being held in Hollywood, FL. Dr.

Pharmacosmos Therapeutics Inc. announced today that it has been established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric® for Iron Deficiency Anemia (IDA) patients in the US. The new company is a subsidiary of the Pharmacosmos Group, a profitable, fast-growing specialty pharmaceutica

Origin Agritech Ltd. updates the progress of biotech research programs and strategies for the commercialization of GMO corn seeds and traits.